The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau.
Acrodermatitis continua of Hallopeau (ACH) is a rare form of pustular psoriasis which poses a challenge to treat and causes considerable pain and suffering for those afflicted. Tumor necrosis factor-alpha (TNF-alpha) is a pro-inflammatory cytokine involved in the pathogenesis of ACH and other forms of psoriasis. Inhibition of TNF-alpha has been shown to provide benefit in such inflammatory conditions as rheumatoid arthritis, psoriatic arthritis, and, most recently, plaque psoriasis. In this report, we present the case of a 65-year-old man with a 9-year history of recalcitrant ACH who demonstrated significant and sustained clinical improvement when etanercept, a competitive inhibitor of TNF-alpha, was added to his treatment regimen of acitretin and topical corticosteroids over a 12-week period.
Kazinski
Kimberly
K
Department of Dermatology, San Antonio Uniformed Services Health Education Consortium, Wilford Hall USAF Medical Center, San Antonio, TX, USA.
Joyce
Kathleen M
KM
Hodson
Darryl
D
D017255:Acitretin / Q000008:administration & dosage*; D000169:Acrodermatitis / Q000188:drug therapy* / Q000473:pathology; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000368:Aged; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*
D000305:Adrenal Cortex Hormones; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D017255:Acitretin; D000068800:Etanercept